<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">ANG</journal-id>
<journal-id journal-id-type="hwp">spang</journal-id>
<journal-id journal-id-type="nlm-ta">Angiology</journal-id>
<journal-title>Angiology</journal-title>
<issn pub-type="ppub">0003-3197</issn>
<issn pub-type="epub">1940-1574</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0003319712453645</article-id>
<article-id pub-id-type="publisher-id">10.1177_0003319712453645</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Diabetes</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>The ε4 Allele of the APOE Gene Is Associated With More Severe Peripheral Neuropathy in Type 2 Diabetic Patients</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Monastiriotis</surname>
<given-names>C.</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0003319712453645">1</xref>
<xref ref-type="corresp" rid="corresp1-0003319712453645"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Papanas</surname>
<given-names>N.</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0003319712453645">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Trypsianis</surname>
<given-names>G.</given-names>
</name>
<degrees>BSc, MA</degrees>
<xref ref-type="aff" rid="aff2-0003319712453645">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Karanikola</surname>
<given-names>K.</given-names>
</name>
<xref ref-type="aff" rid="aff3-0003319712453645">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Veletza</surname>
<given-names>S.</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="aff3-0003319712453645">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Maltezos</surname>
<given-names>E.</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0003319712453645">1</xref>
</contrib>
</contrib-group>
<aff id="aff1-0003319712453645">
<label>1</label>Outpatient Clinic of the Diabetic Foot, Second Department of Internal Medicine, Democritus University of Thrace, Greece</aff>
<aff id="aff2-0003319712453645">
<label>2</label>Department of Medical Statistics, Medical School, Democritus University of Thrace, Greece</aff>
<aff id="aff3-0003319712453645">
<label>3</label>Laboratory of Medical Biology, Medical School, Democritus University of Thrace, Greece</aff>
<author-notes>
<corresp id="corresp1-0003319712453645">C. Monastiriotis, Outpatient Clinic of the Diabetic Foot, Second Department of Internal Medicine, Democritus University of Thrace, Limnou 7, Alexandroupolis 68100, Greece. Email: <email>c_monastiriotis@yahoo.com</email>
</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>8</month>
<year>2013</year>
</pub-date>
<volume>64</volume>
<issue>6</issue>
<fpage>451</fpage>
<lpage>455</lpage>
<permissions>
<copyright-statement>© The Author(s) 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>We examined the association between the ∊4 allele of the apolipoprotein E gene and severity of peripheral neuropathy in 234 patients with type 2 diabetes mellitus (T2DM). Based on the Neuropathy Disability Score (NDS), patients were divided into group A (NDS ≤6: mild or no neuropathy) and group B (NDS &gt;6: severe neuropathy). In each group, patients were further divided into ∊4 carriers and non-∊4 carriers. In multivariate analysis, a more than 5-fold increased risk of severe neuropathy was associated with ∊4 carrier status (adjusted odds ratio [aOR]: 5.26, 95% confidence interval [CI]: 2.24-12.31, <italic>P</italic> = .0001). The other significant risk factors for severe neuropathy included male gender (aOR: 2.08, 95% CI: 1.05-4.14, <italic>P</italic> = .036), diabetes duration (aOR: 1.05, 95% CI: 1.00-1.09, <italic>P</italic> = .039), and hemoglobin A<sub>1c</sub> (aOR: 1.32, 95% CI: 1.05-1.66, <italic>P</italic> = .020). In conclusion, the ∊4 carrier status appears to be associated with severe peripheral neuropathy in T2DM.</p>
</abstract>
<kwd-group>
<kwd>apolipoprotein E</kwd>
<kwd>diabetes mellitus</kwd>
<kwd>diabetic neuropathy</kwd>
<kwd>genes</kwd>
<kwd>polymorphisms</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-0003319712453645">
<title>Introduction</title>
<p>Peripheral neuropathy is the commonest neurologic manifestation of diabetes mellitus (DM), affecting approximately 30% of patients during their lifetime.<sup>
<xref ref-type="bibr" rid="bibr1-0003319712453645">1</xref>,<xref ref-type="bibr" rid="bibr2-0003319712453645">2</xref>
</sup> It represents the main pathogenesis of foot ulceration.<sup>
<xref ref-type="bibr" rid="bibr3-0003319712453645">3</xref>
<xref ref-type="bibr" rid="bibr4-0003319712453645"/>–<xref ref-type="bibr" rid="bibr5-0003319712453645">5</xref>
</sup> It is also associated with increased morbidity and mortality, posing a vast economic burden.<sup>
<xref ref-type="bibr" rid="bibr4-0003319712453645">4</xref>,<xref ref-type="bibr" rid="bibr6-0003319712453645">6</xref>
</sup>
</p>
<p>Several important factors, notably glycemic control, DM duration, age, smoking, and dyslipidemia contribute to a more rapid deterioration of neuropathy.<sup>
<xref ref-type="bibr" rid="bibr7-0003319712453645">7</xref>
</sup> Nevertheless, it is impressive that both clinical presentation and natural history of diabetic peripheral neuropathy are not entirely predictable based on diabetes duration and degree of glycemic control.<sup>
<xref ref-type="bibr" rid="bibr1-0003319712453645">1</xref>,<xref ref-type="bibr" rid="bibr7-0003319712453645">7</xref>,<xref ref-type="bibr" rid="bibr8-0003319712453645">8</xref>
</sup> Conversely, there is surprising heterogeneity even among patients with similar DM duration and metabolic control.<sup>
<xref ref-type="bibr" rid="bibr1-0003319712453645">1</xref>,<xref ref-type="bibr" rid="bibr8-0003319712453645">8</xref>
</sup> Indeed, some patients develop little neuropathy after long-standing DM, whereas others have evidence of nerve damage as early as during pre-DM.<sup>
<xref ref-type="bibr" rid="bibr9-0003319712453645">9</xref>
</sup> This variability gave rise to the hypothesis that genetic factors may contribute to the pathogenesis of peripheral neuropathy. Several genes have been studied, whose products contribute to metabolic or immunologic pathways related to the pathogenesis of peripheral neuropathy. Among them, the aldose reductase,<sup>
<xref ref-type="bibr" rid="bibr10-0003319712453645">10</xref>
</sup> the protein kinase C,<sup>
<xref ref-type="bibr" rid="bibr11-0003319712453645">11</xref>
</sup> and the Na<sup>+</sup>/K<sup>+</sup> ATPase<sup>
<xref ref-type="bibr" rid="bibr12-0003319712453645">12</xref>
</sup> are the most studied genes, as the respective protein products participate in the major metabolic routes considered to be pathogenic of neuropathy. Furthermore, numerous genes have been studied either in humans or in animal models, such as those encoding for alpha2B adrenoreceptor,<sup>
<xref ref-type="bibr" rid="bibr13-0003319712453645">13</xref>
</sup> metabotropic glutamate receptors,<sup>
<xref ref-type="bibr" rid="bibr14-0003319712453645">14</xref>
</sup> and capsaicin receptor.<sup>
<xref ref-type="bibr" rid="bibr15-0003319712453645">15</xref>
</sup>
</p>
<p>It is acknowledged that lipid disorders play a role in the development of peripheral neuropathy by promoting endothelial dysfunction.<sup>
<xref ref-type="bibr" rid="bibr16-0003319712453645">16</xref>
</sup> Apolipoprotein E (apoE) is a 34 kDa protein consisting of 299 amino acids that plays a fundamental role in the metabolism of plasma cholesterol and triglycerides. The 3 most common isoforms of apoE in humans are ∊2, ∊3, and ∊4 (rare variants have also been identified).<sup>
<xref ref-type="bibr" rid="bibr17-0003319712453645">17</xref>,<xref ref-type="bibr" rid="bibr18-0003319712453645">18</xref>
</sup> They are encoded by the apoE gene that is located in the long arm of chromosome 19. The difference between the isoforms is determined by 2 single nucleotide polymorphisms in exon 4 at amino acid positions 112 and 158.<sup>
<xref ref-type="bibr" rid="bibr17-0003319712453645">17</xref>
<xref ref-type="bibr" rid="bibr18-0003319712453645"/>–<xref ref-type="bibr" rid="bibr19-0003319712453645">19</xref>
</sup> The ∊3 isoform has a cysteine at 112 and arginine at 158; ∊2 has cysteines at both positions; and ∊4 has arginines at both positions.<sup>
<xref ref-type="bibr" rid="bibr19-0003319712453645">19</xref>,<xref ref-type="bibr" rid="bibr20-0003319712453645">20</xref>
</sup> The aforementioned alleles have been documented to exhibit different properties relating to lipid accumulation and the mitigation of oxidative stress. As first described in 1996,<sup>
<xref ref-type="bibr" rid="bibr21-0003319712453645">21</xref>
</sup> ∊2 is the most and ∊4 the least potent in terms of antioxidant properties (∊2 &gt; ∊3 &gt; ∊4).</p>
<p>There is now sufficient data to support an important role of apoE in neural function and repair after injury.<sup>
<xref ref-type="bibr" rid="bibr22-0003319712453645">22</xref>
<xref ref-type="bibr" rid="bibr23-0003319712453645"/>–<xref ref-type="bibr" rid="bibr24-0003319712453645">24</xref>
</sup> There are also several studies demonstrating that the ∊4 isoform is associated with an increased risk of developing neuromuscular diseases.<sup>
<xref ref-type="bibr" rid="bibr20-0003319712453645">20</xref>
</sup> However, its role in diabetic peripheral neuropathy is still controversial: some reports have been positive,<sup>
<xref ref-type="bibr" rid="bibr25-0003319712453645">25</xref>,<xref ref-type="bibr" rid="bibr26-0003319712453645">26</xref>
</sup> but later studies<sup>
<xref ref-type="bibr" rid="bibr16-0003319712453645">16</xref>,<xref ref-type="bibr" rid="bibr27-0003319712453645">27</xref>
</sup> have disputed this association. In addition, this relationship has not been adequately studied in type 2 diabetes mellitus (T2DM). Thus, the aim of our study was to test the hypothesis that the apoE ∊4 allele is a risk factor for severe diabetic peripheral neuropathy in patients with T2DM.</p>
</sec>
<sec id="section2-0003319712453645" sec-type="methods">
<title>Patients and Methods</title>
<sec id="section3-0003319712453645">
<title>Patients</title>
<p>This study included 234 patients (120 males and 114 females) with T2DM, recruited from the outpatient clinic of Metabolism, Obesity and Diabetes, in the Second Department of Internal Medicine at Democritus University of Thrace, Alexandroupolis, Greece. The study was conducted in accordance with the Helsinki Declaration of Human Rights and all patients gave their informed consent. Demographic data, history of diabetes, and other covariates are presented in <xref ref-type="table" rid="table1-0003319712453645">Table 1</xref>.</p>
<table-wrap id="table1-0003319712453645" position="float">
<label>Table 1.</label>
<caption>
<p>Patient Characteristics.</p>
</caption>
<graphic alternate-form-of="table1-0003319712453645" xlink:href="10.1177_0003319712453645-table1.tif"/>
<table>
<thead>
<tr>
<th>Parameter</th>
<th>Range </th>
<th>Median</th>
<th>Mean ± SD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years</td>
<td>37-85 </td>
<td>66 </td>
<td>65.3 ± 8.3 </td>
</tr>
<tr>
<td>Diabetes duration, years</td>
<td>0-38 </td>
<td>11 </td>
<td>12.1 ± 8.0 </td>
</tr>
<tr>
<td>HbA<sub>1c</sub>, %</td>
<td>4.9-14.5</td>
<td>7.9</td>
<td>7.9 ± 1.4</td>
</tr>
<tr>
<td>NDS</td>
<td>0-10</td>
<td>2</td>
<td>3.6 ± 3.5</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0003319712453645">
<p>Abbreviations: HbA<sub>1c</sub>, hemoglobin A<sub>1c</sub>; NDS, Neuropathy Disability Score; SD, standard deviation.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="table2-0003319712453645" position="float">
<label>Table 2.</label>
<caption>
<p>Patient Characteristics in the 2 Groups.</p>
</caption>
<graphic alternate-form-of="table2-0003319712453645" xlink:href="10.1177_0003319712453645-table2.tif"/>
<table>
<thead>
<tr>
<th>Parameters</th>
<th>Group A (NDS ≤6)</th>
<th>Group B (NDS &gt;6)</th>
<th>
<italic>P</italic> Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of patients</td>
<td>180</td>
<td>54</td>
<td>
</td>
</tr>
<tr>
<td>∊4 carriers</td>
<td>16</td>
<td>15</td>
<td>
</td>
</tr>
<tr>
<td>Non-∊4 carriers</td>
<td>164</td>
<td>39</td>
<td>
</td>
</tr>
<tr>
<td>Males, n (%)</td>
<td>87/120 (72.5%)</td>
<td>33/120 (27.5%)</td>
<td rowspan="2">.099</td>
</tr>
<tr>
<td>Females, n (%)</td>
<td>93/114 (81.6%)</td>
<td>21/114 (18.4%)</td>
</tr>
<tr>
<td>Diabetes duration, years (median [range])</td>
<td>10 (0-38) </td>
<td>12 (1-36) </td>
<td>.014</td>
</tr>
<tr>
<td>HbA<sub>1c</sub>, %, mean ± SD</td>
<td>7.8 ± 1.4</td>
<td>8.3 ± 1.5</td>
<td>.029</td>
</tr>
<tr>
<td>Age, years, mean ± SD</td>
<td>64.9 ± 8.3 </td>
<td>66.7 ± 8.1 </td>
<td>.171</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn2-0003319712453645">
<p>Abbreviations: HbA<sub>1c</sub>, hemoglobin A<sub>1c</sub>; NDS, Neuropathy Disability Score; SD, standard deviation.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Exclusion criteria were chronic alcohol abuse, thyroid disease, vitamin B<sub>12</sub> depletion, lumbar spine disorders, neurotoxic agents, or any other cause of peripheral neuropathy.</p>
</sec>
<sec id="section4-0003319712453645">
<title>Clinical Examination</title>
<p>All patients underwent clinical examination to identify the presence and severity of diabetic peripheral neuropathy. The examiner was kept blind to the patients’ apoE genotype status. Examination included Achilles tendon reflexes, vibration perception at the hallux using a 128 Hz graded tuning fork, pin-prick, and temperature sensation in both feet. These clinical signs were scored according to the Neuropathy Disability Score (NDS),<sup>
<xref ref-type="bibr" rid="bibr2-0003319712453645">2</xref>
</sup> a widely used scoring system of peripheral neuropathy (lowest score 0 denoting absence of neuropathy and highest score 10 representing the most severe neuropathy).</p>
<p>According to NDS, patients were divided into group A (180 patients with mild or no neuropathy, based on NDS ≤6) and group B (54 patients with severe neuropathy, based on NDS &gt;6). The cutoff 6 was selected for 2 reasons: first, prior studies have used it to distinguish mild from severe neuropathy,<sup>
<xref ref-type="bibr" rid="bibr3-0003319712453645">3</xref>,<xref ref-type="bibr" rid="bibr28-0003319712453645">28</xref>,<xref ref-type="bibr" rid="bibr29-0003319712453645">29</xref>
</sup> and second, there is evidence that the risk of foot ulceration rises significantly in patients with an NDS ≥6.<sup>
<xref ref-type="bibr" rid="bibr30-0003319712453645">30</xref>
</sup> In addition, this value was the limit of the 75th percentile of NDS values in our patient series.</p>
</sec>
<sec id="section5-0003319712453645">
<title>Laboratory Procedure—apoE Genotyping</title>
<p>Genotyping of apoE was performed after DNA was extracted from 0.5 mL of whole blood as described previously.<sup>
<xref ref-type="bibr" rid="bibr19-0003319712453645">19</xref>,<xref ref-type="bibr" rid="bibr31-0003319712453645">31</xref>
</sup> Genotyping was carried out by polymerase chain reaction (PCR) using 50 to 100 ng of DNA and the following primers, in a modification of previously described procedure,<sup>
<xref ref-type="bibr" rid="bibr19-0003319712453645">19</xref>,<xref ref-type="bibr" rid="bibr32-0003319712453645">32</xref>
</sup> published in Karpouzis et al<sup>
<xref ref-type="bibr" rid="bibr33-0003319712453645">33</xref>
</sup>: 1EF<sub>2</sub> (5′-ACAGAATTCGCCCCGGCCTGGTACACTGCCA-3′) and 2AER (5′-TAAGCTTGGCACGGCTGTCCAA-3′).</p>
<p>The PCR involved 40 successive cycles at 95°C for 1 minute, 60°C for 1 minute, 70°C for 2 minutes, and resulted in a 244 base pair-long amplicon that included both polymorphic sites. Digestion of the PCR product by the restriction enzyme <italic>Hha</italic>I produced the following fragments: allele ∊2: 91, 81, 38, 18, 16; allele ∊3: 91, 48, 38, 33, 18, 16; and allele ∊4: 72, 48, 38, 33, 19, 18, 16. Patients with no/mild and with severe neuropathy were divided into the “∊4 carrier” and the “non-∊4 carrier” subgroups.</p>
</sec>
<sec id="section6-0003319712453645">
<title>Statistical Analysis</title>
<p>Statistical analysis was performed using the Statistical Package for the Social Sciences (SPSS), version 19.0. The normality of continuous variables was tested with the Kolmogorov-Smirnov test. Normally distributed continuous variables were expressed as the mean ± standard deviation, while nonnormally distributed variables were expressed as the median and range; they were analyzed using Student <italic>t</italic> test and Mann-Whitney <italic>U</italic> test, respectively. Categorical variables were expressed as frequencies and percentages. Chi-square test was used to evaluate any potential association between categorical variables. It was also used to compare the observed frequency of apoE genotype with that expected for a population in Hardy-Weinberg equilibrium. To evaluate the risk of severe neuropathy according to ∊4 carrier status, multivariate logistic regression analysis was conducted with adjustment for gender, age, T2DM duration, and hemoglobin A<sub>1c</sub> (HbA<sub>1c</sub>) level. Odd ratios (ORs) and their 95% confidence intervals (CIs) were calculated as the measure of association between patient characteristics and severe neuropathy. All tests were 2-tailed and significance was considered for <italic>P</italic> values &lt; .05.</p>
</sec>
</sec>
<sec id="section7-0003319712453645">
<title>Results</title>
<p>The frequencies of genotypes in our population sample were 8.5% for ∊2/∊3 (20 patients), 78.2% for ∊3/∊3 (183 patients), and 13.3% for ∊3/∊4 (31 patients) while no one had the ∊2/∊2, ∊4/∊4, or ∊2/∊4 genotypes. Thus, 31 patients were ∊4 carriers (13.3%) and 313 patients (86.7%) were non-∊4 carriers. The genotype distribution was in Hardy-Weinberg equilibrium (χ<sup>
<xref ref-type="bibr" rid="bibr2-0003319712453645">2</xref>
</sup> = 3.500, <italic>df</italic> = 3, <italic>P</italic> = .321).</p>
<p>According to NDS, severe neuropathy (NDS &gt;6) was insignificantly more frequent among males than females (27.5% vs 18.4%, <italic>P</italic> = .099). Furthermore, patients in group B had longer T2DM duration (12 [1-36] vs 10 [0-38] years, <italic>P</italic> = .014) and higher HbA<sub>1c</sub> (8.3 ± 1.5% vs 7.8 ± 1.4%, <italic>P</italic> = .029) compared with patients with mild neuropathy. The 2 groups did not differ in age (group A: 64.9 ± 8.3 years vs group B: 66.7 ± 8.1 years, <italic>P</italic> = .171). Overall, ∊4 carrier status was significantly more frequent in group B (15 patients, 27.8%), compared with group A (16 patients, 8.9%; <italic>P</italic> = .0003, OR: 3.94; 95% CI: 1.80-8.65).</p>
<p>In multivariate logistic regression analysis, a more than 5-fold increase in risk of severe neuropathy was associated with ∊4 carrier status (adjusted OR [aOR]: 5.26, 95% CI: 2.24-12.31, <italic>P</italic> = .0001) compared to non-∊4 carrier status (<xref ref-type="fig" rid="fig1-0003319712453645">Figure 1</xref>). The other significant risk factors for severe neuropathy included male gender (aOR: 2.08, 95% CI: 1.05-4.14, <italic>P</italic> = .036), T2DM duration (aOR: 1.05, 95% CI: 1.00-1.09, <italic>P</italic> = .039), and HbA<sub>1c</sub> (aOR: 1.32, 95% CI: 1.05-1.66, <italic>P</italic> = .020; <xref ref-type="fig" rid="fig2-0003319712453645">Figure 2</xref>), while a marginal effect of age was also found (aOR: 1.04, 95% CI: 0.99-1.08, <italic>P</italic> = .091).</p>
<fig id="fig1-0003319712453645" position="float">
<label>Figure 1.</label>
<caption>
<p>Adjusted odds ratio (aOR) of ∊4 carrier status for severe peripheral neuropathy.</p>
</caption>
<graphic xlink:href="10.1177_0003319712453645-fig1.tif"/>
</fig>
<fig id="fig2-0003319712453645" position="float">
<label>Figure 2.</label>
<caption>
<p>Adjusted odds ratios (aORs) of male gender, age (in years), diabetes duration (in years), and hemoglobin A<sub>1c</sub> ([HbA<sub>1c</sub>] in percentage) for severe peripheral neuropathy.</p>
</caption>
<graphic xlink:href="10.1177_0003319712453645-fig2.tif"/>
</fig>
</sec>
<sec id="section8-0003319712453645">
<title>Discussion</title>
<p>Our major finding is a more than 5-fold increase in the risk of severe peripheral diabetic neuropathy in ∊4 carriers with T2DM, after adjustment for covariates. This finding agrees with the studies by Tsuzuki et al<sup>
<xref ref-type="bibr" rid="bibr25-0003319712453645">25</xref>
</sup> and by Bedlack et al.<sup>
<xref ref-type="bibr" rid="bibr26-0003319712453645">26</xref>
</sup> Both these studies have provided evidence that ∊4 carrier status is associated with more severe neuropathy. However, the former used a subjective self-devised examination system to diagnose neuropathy, rather than a standardized clinical scale, as in our study; the latter included patients with both diabetes types and not exclusively T2DM. More importantly, the 2 prior studies<sup>
<xref ref-type="bibr" rid="bibr25-0003319712453645">25</xref>,<xref ref-type="bibr" rid="bibr26-0003319712453645">26</xref>
</sup> did not perform multivariate analysis to adjust for confounders (notably age, gender, and diabetes duration). In contrast, 2 more recent works<sup>
<xref ref-type="bibr" rid="bibr16-0003319712453645">16</xref>,<xref ref-type="bibr" rid="bibr27-0003319712453645">27</xref>
</sup> found no association between ∊4 carrier status and frequency or severity of peripheral neuropathy. Nevertheless, Voron’ko et al<sup>
<xref ref-type="bibr" rid="bibr16-0003319712453645">16</xref>
</sup> used a different patient series (T1DM) and, again, did not adjust for covariates. Zhou et al<sup>
<xref ref-type="bibr" rid="bibr27-0003319712453645">27</xref>
</sup> also examined a different population (small series of patients with unidentified neuropathy) and used a different method for apoE genotyping (based on skin biopsy). Taken together, conflicting results may reflect methodological differences (severity scales and patient group distinction) or real genetic differences between the studied populations (as already recognized for apoE),<sup>
<xref ref-type="bibr" rid="bibr34-0003319712453645">34</xref>
<xref ref-type="bibr" rid="bibr35-0003319712453645"/>–<xref ref-type="bibr" rid="bibr36-0003319712453645">36</xref>
</sup> due to the potential interference of other genes that may affect the contribution of apoE isoforms to the pathogenesis of diabetic peripheral neuropathy. Our study has included the largest patient series so far, used a standardized clinical neuropathy scale with a widely accepted cutoff for severe neuropathy, and adjusted for age, gender, diabetes duration, and HbA<sub>1c</sub> level.</p>
<p>In the context of studying the role of genes in the pathogenesis of diabetic neuropathy, apoE gene polymorphisms are of special interest. Indeed, apoE, synthesized by glial cells, is the main apolipoprotein in the central nervous system.<sup>
<xref ref-type="bibr" rid="bibr37-0003319712453645">37</xref>
</sup> It is also found in the peripheral nervous system, where it is produced by nonmyelinating Schwann cells, ganglionic satellite cells, and macrophages.<sup>
<xref ref-type="bibr" rid="bibr38-0003319712453645">38</xref>
</sup> Apart from its role in regulating plasma lipids and their metabolism, apoE is thought to exert potent antioxidant properties, thereby mitigating oxidative stress at the neuronal level.<sup>
<xref ref-type="bibr" rid="bibr38-0003319712453645">38</xref>,<xref ref-type="bibr" rid="bibr39-0003319712453645">39</xref>
</sup> In terms of this function, the ∊4 allele is slightly deficient, so that its carriers are less well protected from oxidative cellular (primarily neuronal) stress.<sup>
<xref ref-type="bibr" rid="bibr39-0003319712453645">39</xref>,<xref ref-type="bibr" rid="bibr40-0003319712453645">40</xref>
</sup> This may partly explain its correlation with worse course in Alzheimer disease<sup>
<xref ref-type="bibr" rid="bibr41-0003319712453645">41</xref>
<xref ref-type="bibr" rid="bibr42-0003319712453645"/>
<xref ref-type="bibr" rid="bibr43-0003319712453645"/>–<xref ref-type="bibr" rid="bibr44-0003319712453645">44</xref>
</sup> but also in cardiovascular disease.<sup>
<xref ref-type="bibr" rid="bibr45-0003319712453645">45</xref>
</sup> There is also some evidence that apoE gene polymorphisms affect the course of other neuromuscular diseases and disorders.<sup>
<xref ref-type="bibr" rid="bibr20-0003319712453645">20</xref>
</sup> Of particular note, research in peripheral nervous system diseases has, generally, confirmed the adverse role of the ∊4 allele.<sup>
<xref ref-type="bibr" rid="bibr20-0003319712453645">20</xref>
</sup> This evidence supports our finding that this allele is associated with more severe diabetic peripheral neuropathy.</p>
<p>Our study has its limitations. First, it recruited patients from a tertiary center, and so its results are not entirely applicable to the general diabetic population. Second, it cannot answer whether ∊4 carrier status is a risk factor for the future development of peripheral neuropathy. Such question would need a prospective study.</p>
<p>In terms of practical implications, our findings suggest that in patients with T2DM, the presence of the ∊4 allele is associated with a high risk of severe peripheral neuropathy, even after adjustment for covariates. First, this finding could be used to guide further investigation of the pathogenesis of neuropathy. Indeed, it might, theoretically, be possible to develop agents interfering with causal pathways and preventing or delaying the progress of peripheral neuropathy. Second, it justifies the question whether screening of T2DM patients for the ∊4 allele and more intense health care of ∊4 carriers might be of some value in reducing the burden of diabetic neuropathy. Naturally, large population studies, including people of different origin and fully adjusting for covariates, are required to provide a definitive answer. Such studies could ascertain whether it is cost-effective to genotype all diabetic patients on diagnosis and treat ∊4 carriers more vigorously, or, alternatively, whether it would be preferable to improve standard care for all. Ideally, the latter should nowadays attempt to address additional risk factors, such as uric acid,<sup>
<xref ref-type="bibr" rid="bibr46-0003319712453645">46</xref>
</sup> impaired microcirculation,<sup>
<xref ref-type="bibr" rid="bibr47-0003319712453645">47</xref>
</sup> and oxidative stress.<sup>
<xref ref-type="bibr" rid="bibr48-0003319712453645">48</xref>
</sup>
</p>
<p>In conclusion, the ∊4 allele of the apoE gene appears to confer a high risk of severe peripheral neuropathy in T2DM. While this result may open new perspectives in the understanding of pathophysiology and to prompt the investigation of new treatment options, it needs to be confirmed in large population studies. Meanwhile, strict glycemic control and management of cardiovascular risk factors, along with early diagnosis of neuropathy, remain the only available management strategies for diabetic peripheral neuropathy.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="conflict" id="fn1-0003319712453645">
<label>Declaration of Conflicting Interests</label>
<p>The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Dr N. Papanas has been an advisory board member of TrigoCare International; has participated in sponsored studies by Novo Nordisk and Novartis; has received honoraria as a speaker for Novo Nordisk and Pfizer; and attended conferences sponsored by TrigoCare International, Novo Nordisk, Sanofi-Aventis and Pfizer. Professor E. Maltezos has participated in sponsored studies by Novo Nordisk and Novartis and attended conferences sponsored by Wyeth, Pfizer, and Bayer.</p>
</fn>
<fn fn-type="financial-disclosure" id="fn2-0003319712453645">
<label>Funding</label>
<p>The authors received no financial support for the research, authorship, and/or publication of this article.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0003319712453645">
<label>1</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Shaw</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Zimmet</surname>
<given-names>PZ</given-names>
</name>
<name>
<surname>Gries</surname>
<given-names>FA</given-names>
</name>
<name>
<surname>Ziegler</surname>
<given-names>D</given-names>
</name>
</person-group>. <article-title>Epidemiology of diabetic neuropathy</article-title>. In: <person-group person-group-type="editor">
<name>
<surname>C</surname>
<given-names>Gries</given-names>
</name>
<name>
<surname>Ziegler</surname>
<given-names>Low</given-names>
</name>
</person-group>, eds. <source>Textbook of Diabetic Neuropathy</source>. <publisher-loc>New York, NY</publisher-loc>: <publisher-name>Thieme Verlag</publisher-name>, <year>2003</year>:<fpage>64</fpage>–<lpage>79</lpage>.</citation>
</ref>
<ref id="bibr2-0003319712453645">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Young</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Boulton</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Macleod</surname>
<given-names>AF</given-names>
</name>
<name>
<surname>Williams</surname>
<given-names>DR</given-names>
</name>
<name>
<surname>Sonksen</surname>
<given-names>PH</given-names>
</name>
</person-group>. <article-title>A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population</article-title>. <source>Diabetologia</source>. <year>1993</year>;<volume>36</volume>(<issue>2</issue>):<fpage>150</fpage>–<lpage>154</lpage>.</citation>
</ref>
<ref id="bibr3-0003319712453645">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Boulton</surname>
<given-names>AJ</given-names>
</name>
</person-group>. <article-title>The diabetic foot: grand overview, epidemiology and pathogenesis</article-title>. <source>Diabetes Metab Res Rev</source>. <year>2008</year>;<volume>24</volume>(<issue>suppl 1</issue>):<fpage>S3</fpage>–<lpage>S6</lpage>.</citation>
</ref>
<ref id="bibr4-0003319712453645">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Edmonds</surname>
<given-names>ME</given-names>
</name>
</person-group>, <article-title>The diabetic foot, 2003</article-title>. <source>Diabetes Metal Res Rev</source>. <year>2004</year>;<volume>20</volume>(<issue>suppl 1</issue>):<fpage>S9</fpage>–<lpage>S12</lpage>.</citation>
</ref>
<ref id="bibr5-0003319712453645">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ziegler</surname>
<given-names>D</given-names>
</name>
</person-group>. <article-title>Painful diabetic neuropathy: advantage of novel drugs over old drugs?</article-title> <source>Diabetes Care</source>. <year>2009</year>;<volume>32</volume>(<issue>suppl 2</issue>):<fpage>S414</fpage>–<lpage>S419</lpage>.</citation>
</ref>
<ref id="bibr6-0003319712453645">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tesfaye</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Boulton</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Dyck</surname>
<given-names>PJ</given-names>
</name>
<etal/>
</person-group>. <article-title>Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments</article-title>. <source>Diabetes Care</source>. <year>2010</year>;<volume>33</volume>(<issue>10</issue>):<fpage>2285</fpage>–<lpage>2293</lpage>.</citation>
</ref>
<ref id="bibr7-0003319712453645">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dyck</surname>
<given-names>PJ</given-names>
</name>
<name>
<surname>Davies</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Wilson</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Service</surname>
<given-names>FJ</given-names>
</name>
<name>
<surname>Melton</surname>
<given-names>LJ</given-names>
<suffix> 3rd</suffix>
</name>
<name>
<surname>O’Brien</surname>
<given-names>PC</given-names>
</name>
</person-group>. <article-title>Risk factors for severity of diabetic polyneuropathy: intensive longitudinal assessment of the Rochester Diabetic Neuropathy Study cohort</article-title>. <source>Diabetes Care</source>. <year>1999</year>:<volume>22</volume>(<issue>9</issue>):<fpage>1479</fpage>–<lpage>1486</lpage>.</citation>
</ref>
<ref id="bibr8-0003319712453645">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Várkonyi</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Kempler</surname>
<given-names>P</given-names>
</name>
</person-group>. <article-title>Diabetic neuropathy: new strategies for treatment</article-title>. <source>Diabetes Obes Metab</source>. <year>2008</year>;<volume>10</volume>(<issue>2</issue>):<fpage>99</fpage>–<lpage>108</lpage>.</citation>
</ref>
<ref id="bibr9-0003319712453645">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Papanas</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Vinik</surname>
<given-names>AI</given-names>
</name>
<name>
<surname>Ziegler</surname>
<given-names>D</given-names>
</name>
</person-group>. <article-title>Neuropathy in prediabetes: does the clock start ticking early</article-title>. <source>Nat Rev Endocrinol</source>. <year>2011</year>;<volume>7</volume>(<issue>11</issue>):<fpage>682</fpage>–<lpage>690</lpage>.</citation>
</ref>
<ref id="bibr10-0003319712453645">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sivenius</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Pihlajamaki</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Partanen</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Niskanen</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Laakso</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Uusitupa</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>Aldose reductase gene polymorphisms and peripheral nerve function in patients with type 2 diabetes</article-title>. <source>Diabetes Care</source>. <year>2004</year>;<volume>27</volume>(<issue>8</issue>):<fpage>2021</fpage>–<lpage>2026</lpage>.</citation>
</ref>
<ref id="bibr11-0003319712453645">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Way</surname>
<given-names>KJ</given-names>
</name>
<name>
<surname>Katai</surname>
<given-names>N</given-names>
</name>
<name>
<surname>King</surname>
<given-names>GL</given-names>
</name>
</person-group>. <article-title>Protein kinase C and the development of diabetic vascular complications</article-title>. <source>Diabet Med</source>. <year>2001</year>;<volume>18</volume>(<issue>12</issue>):<fpage>945</fpage>–<lpage>959</lpage>.</citation>
</ref>
<ref id="bibr12-0003319712453645">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vague</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Dufayet</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Coste</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Moriscot</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Jannot</surname>
<given-names>MF</given-names>
</name>
<name>
<surname>Raccah</surname>
<given-names>D</given-names>
</name>
</person-group>. <article-title>Association of diabetic neuropathy with Na/K ATPase gene polymorphism</article-title>. <source>Diabetologia</source>. <year>1997</year>;<volume>40</volume>(<issue>5</issue>):<fpage>506</fpage>–<lpage>511</lpage>.</citation>
</ref>
<ref id="bibr13-0003319712453645">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Papanas</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Papatheodorou</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Papazoglou</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Kotsiou</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Christakidis</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Maltezos</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>An insertion/deletion polymorphism in the Alpha2B adrenoreceptor gene is associated with peripheral neuropathy in patients with type 2 diabetes mellitus</article-title>. <source>Exp Clin Endocrinol Diabetes</source>. <year>2007</year>;<volume>115</volume>(<issue>5</issue>):<fpage>327</fpage>–<lpage>330</lpage>.</citation>
</ref>
<ref id="bibr14-0003319712453645">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Anjaneyulu</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Berent-Spillson</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Russel</surname>
<given-names>JW</given-names>
</name>
</person-group>. <article-title>Metabotropic glutamate receptors (mGluRs) and diabetic neuropathy</article-title>. <source>Curr Drug Targets</source>. <year>2008</year>;<volume>9</volume>(<issue>1</issue>):<fpage>85</fpage>–<lpage>93</lpage>.</citation>
</ref>
<ref id="bibr15-0003319712453645">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Facer</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Casula</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>GD</given-names>
</name>
<etal/>
</person-group>. <article-title>Differential expression of the capsaicin receptor TRPV I and related novel receptors TRPV3, TRPV4 and TRPM8 in normal human tissues and changes in traumatic and diabetic neuropathy</article-title>. <source>BMC Neurol</source>. <year>2007</year>;<volume>7</volume>:<fpage>11</fpage>.</citation>
</ref>
<ref id="bibr16-0003319712453645">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Voron’ko</surname>
<given-names>OE</given-names>
</name>
<name>
<surname>Lakunina</surname>
<given-names>NIu</given-names>
</name>
<name>
<surname>Strokov</surname>
<given-names>IA</given-names>
</name>
<name>
<surname>Lavrova</surname>
<given-names>IN</given-names>
</name>
<name>
<surname>Nosikov</surname>
<given-names>VV.</given-names>
</name>
</person-group> <article-title>[Association of polymorphic markers of the lipid metabolism genes with diabetic neuropathy in type 1 diabetes mellitus.]</article-title> <source>Mol Biol (Mosk)</source>. <year>2005</year>;<volume>39</volume>(<issue>2</issue>):<fpage>230</fpage>–<lpage>234</lpage>.</citation>
</ref>
<ref id="bibr17-0003319712453645">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mahley</surname>
<given-names>RW</given-names>
</name>
</person-group>. <article-title>Apolipoprotein E cholesterol transport protein with expanding role in cell biology</article-title>. <source>Science</source>. <year>1988</year>;<volume>240</volume>(<issue>4852</issue>):<fpage>622</fpage>–<lpage>630</lpage>.</citation>
</ref>
<ref id="bibr18-0003319712453645">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ordovas</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Litwack-Klein</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Wilson</surname>
<given-names>PW</given-names>
</name>
<name>
<surname>Schaefer</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Schaefer</surname>
<given-names>EJ</given-names>
</name>
</person-group>. <article-title>Apolipoprotein E isoform phenotyping methodology and population frequency with identification of apoE1 and apoE5 isoforms</article-title>. <source>J Lipid Res</source>. <year>1987</year>;<volume>28</volume>(<issue>4</issue>):<fpage>371</fpage>–<lpage>380</lpage>.</citation>
</ref>
<ref id="bibr19-0003319712453645">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hixxson JE Vernier</surname>
<given-names>DT</given-names>
</name>
</person-group>. <article-title>Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with Hha I</article-title>. <source>J Lipid Res</source>. <year>1990</year>;<volume>31</volume>(<issue>3</issue>):<fpage>545</fpage>–<lpage>548</lpage>.</citation>
</ref>
<ref id="bibr20-0003319712453645">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bedlack</surname>
<given-names>RS</given-names>
</name>
<name>
<surname>Strittmatter</surname>
<given-names>WJ</given-names>
</name>
<name>
<surname>Morgenlander</surname>
<given-names>JC</given-names>
</name>
</person-group>. <article-title>Apolipoprotein E and neuromuscular disease: a critical review of literature</article-title>. <source>Arch Neurol</source>. <year>2000</year>;<volume>57</volume>(<issue>11</issue>):<fpage>1561</fpage>–<lpage>1565</lpage>.</citation>
</ref>
<ref id="bibr21-0003319712453645">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Miyata</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>JD</given-names>
</name>
</person-group>. <article-title>Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and beta-amyloid peptides</article-title>. <source>Nat Genet</source>. <year>1996</year>;<volume>14</volume>(<issue>1</issue>):<fpage>55</fpage>–<lpage>61</lpage>.</citation>
</ref>
<ref id="bibr22-0003319712453645">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Boyles</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Pitas</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Wilson</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Mahley</surname>
<given-names>RW</given-names>
</name>
<name>
<surname>Taylor</surname>
<given-names>JM</given-names>
</name>
</person-group>. <article-title>Apolipoprotein E associated with astrocytic glia of the central nervous system and with nonmyelinating glia of the peripheral nervous system</article-title>. <source>J Clin Invest</source>. <year>1985</year>;<volume>76</volume>(<issue>4</issue>):<fpage>1501</fpage>–<lpage>1513</lpage>.</citation>
</ref>
<ref id="bibr23-0003319712453645">
<label>23</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Skene</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Shooter</surname>
<given-names>E</given-names>
</name>
</person-group>. <article-title>Denervated sheath cells secrete a new protein after nerve injury</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>1983</year>;<volume>80</volume>(<issue>13</issue>):<fpage>4169</fpage>–<lpage>4173</lpage>.</citation>
</ref>
<ref id="bibr24-0003319712453645">
<label>24</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gelman</surname>
<given-names>BB</given-names>
</name>
<name>
<surname>Rifai</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Goodrum</surname>
<given-names>JF</given-names>
</name>
<name>
<surname>Bouldin</surname>
<given-names>TW</given-names>
</name>
<name>
<surname>Krigman</surname>
<given-names>MR</given-names>
</name>
</person-group>. <article-title>Apolipoprotein E is released by rat sciatic nerve during segmental demyelination and remyelination</article-title>. <source>J Neuropathol Exp Neurol</source>. <year>1987</year>;<volume>46</volume>(<issue>6</issue>):<fpage>644</fpage>–<lpage>652</lpage>.</citation>
</ref>
<ref id="bibr25-0003319712453645">
<label>25</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tsuzuki</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Murano</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Watanabe</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Itoh</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Miyashita</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Shirai</surname>
<given-names>K.</given-names>
</name>
</person-group> <article-title>[The examination of apoE phenotypes in diabetic patients with peripheral neuropathy.]</article-title> <source>Rinsho Byori</source>. <year>1998</year>;<volume>46</volume>(<issue>8</issue>):<fpage>829</fpage>–<lpage>833</lpage>.</citation>
</ref>
<ref id="bibr26-0003319712453645">
<label>26</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bedlack</surname>
<given-names>RS</given-names>
</name>
<name>
<surname>Edelman</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Gibbs</surname>
<given-names>JW</given-names>
<suffix> 3rd</suffix>
</name>
<etal/>
</person-group>. <article-title>APOE genotype is a risk factor for neuropathy severity in diabetic patients</article-title>. <source>Neurology</source>. <year>2003</year>;<volume>60</volume>(<issue>6</issue>):<fpage>1022</fpage>–<lpage>1024</lpage>.</citation>
</ref>
<ref id="bibr27-0003319712453645">
<label>27</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Hoke</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Cornblath</surname>
<given-names>DR</given-names>
</name>
<name>
<surname>Griffin</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Polydefkis</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>APOE epsilon4 is not a succeptibility gene in idiopathic or diabetic sensory neuropathy</article-title>. <source>Neurology</source>. <year>2005</year>;<volume>64</volume>(<issue>1</issue>):<fpage>139</fpage>–<lpage>141</lpage>.</citation>
</ref>
<ref id="bibr28-0003319712453645">
<label>28</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Paisley</surname>
<given-names>AN</given-names>
</name>
<name>
<surname>Abbott</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>van Schie</surname>
<given-names>CH</given-names>
</name>
<name>
<surname>Boulton</surname>
<given-names>AJ</given-names>
</name>
</person-group>. <article-title>A comparison of the Neuropen against standard quantitative sensory-threshold measures for assessing peripheral nerve function</article-title>. <source>Diabet Med</source>. <year>2002</year>;<volume>19</volume>(<issue>5</issue>):<fpage>400</fpage>–<lpage>405</lpage>.</citation>
</ref>
<ref id="bibr29-0003319712453645">
<label>29</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Papanas</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Papatheodorou</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Papazoglou</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Monastiriotis</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Christakidis</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Maltezos</surname>
<given-names>E</given-names>
</name>
</person-group>. <article-title>A comparison of the new indicator test for sudomotor function (Neuropad<sup>®</sup>) with the vibration perception threshold and the clinical examination in the diagnosis of peripheral neuropathy in subjects with type 2 diabetes</article-title>. <source>Exp Clin Endocrinol Diabetes</source>. <year>2008</year>;<volume>116</volume>(<issue>2</issue>):<fpage>135</fpage>–<lpage>138</lpage>.</citation>
</ref>
<ref id="bibr30-0003319712453645">
<label>30</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Abbott</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Carrington</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Ashe</surname>
<given-names>H</given-names>
</name>
<etal/>
</person-group>. <article-title>The North-West Diabetes Foot Care Study: incidence of, and risk factors for, new diabetic foot ulceration in a community-based patient cohort</article-title>. <source>Diabet Med</source>. <year>2002</year>;<volume>19</volume>(<issue>5</issue>):<fpage>377</fpage>–<lpage>384</lpage>.</citation>
</ref>
<ref id="bibr31-0003319712453645">
<label>31</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Miller</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Dykes</surname>
<given-names>DD</given-names>
</name>
<name>
<surname>Polesky</surname>
<given-names>HF</given-names>
</name>
</person-group>. <article-title>A simple salting out procedure for extracting DNA from human nucleated cells</article-title>. <source>Nucleic Acids Res</source>. <year>1988</year>;<volume>16</volume>(<issue>3</issue>):<fpage>1215</fpage>.</citation>
</ref>
<ref id="bibr32-0003319712453645">
<label>32</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Reymer</surname>
<given-names>PW</given-names>
</name>
<name>
<surname>Groenemeyer</surname>
<given-names>BE</given-names>
</name>
<name>
<surname>van de Burg</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Kastelein</surname>
<given-names>JJ</given-names>
</name>
</person-group>. <article-title>Apolipoprotein E genotyping on agarose gels</article-title>. <source>Clin Chem</source>. <year>1995</year>;<volume>41</volume>(<issue>7</issue>):<fpage>1046</fpage>–<lpage>1047</lpage>.</citation>
</ref>
<ref id="bibr33-0003319712453645">
<label>33</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Karpouzis</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Caridha</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Tripsianis</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Michailidis</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Martinis</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Veletza</surname>
<given-names>SV.</given-names>
</name>
</person-group> <article-title>Apolipoprotein E gene polymorphism in psoriasis</article-title>. <source>Arch Dermatol Res</source>. <year>2009</year>;<volume>301</volume>(<issue>6</issue>):<fpage>405</fpage>–<lpage>410</lpage>.</citation>
</ref>
<ref id="bibr34-0003319712453645">
<label>34</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sklavounou</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Economou-Petersen</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Karadima</surname>
<given-names>G</given-names>
</name>
<etal/>
</person-group>. <article-title>Apolipoprotein E polymorphism in the Greek population</article-title>. <source>Clin Genet</source>. <year>1997</year>;<volume>52</volume>(<issue>4</issue>):<fpage>216</fpage>–<lpage>218</lpage>.</citation>
</ref>
<ref id="bibr35-0003319712453645">
<label>35</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kolovou</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Daskalova</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Mikhailidis</surname>
<given-names>DP</given-names>
</name>
</person-group>. <article-title>Apolipoprotein E polymorphism and atherosclerosis</article-title>. <source>Angiology</source>. <year>2003</year>;<volume>54</volume>(<issue>1</issue>):<fpage>59</fpage>–<lpage>71</lpage>.</citation>
</ref>
<ref id="bibr36-0003319712453645">
<label>36</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kolovou</surname>
<given-names>GD</given-names>
</name>
<name>
<surname>Anagnostopoulou</surname>
<given-names>KK</given-names>
</name>
<name>
<surname>Mikhailidis</surname>
<given-names>DP</given-names>
</name>
<etal/>
</person-group>. <article-title>Association of apolipoprotein E genotype with early onset of coronary heart disease in Greek men</article-title>. <source>Angiology</source>. <year>2005</year>;<volume>56</volume>(<issue>6</issue>):<fpage>663</fpage>–<lpage>670</lpage>.</citation>
</ref>
<ref id="bibr37-0003319712453645">
<label>37</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pitas</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Boyles</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Foss</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Mahley</surname>
<given-names>RW</given-names>
</name>
</person-group>. <article-title>Astrocytes synthesize apolipoprotein E and metabolize apolipoprotein E-containing lipoproteins</article-title>. <source>Biochim Biophys Acta</source>. <year>1987</year>;<volume>917</volume>(<issue>1</issue>):<fpage>148</fpage>–<lpage>161</lpage>.</citation>
</ref>
<ref id="bibr38-0003319712453645">
<label>38</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Smith</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Miyata</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Poulin</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Neveux</surname>
<given-names>LM</given-names>
</name>
<name>
<surname>Craig</surname>
<given-names>WY</given-names>
</name>
</person-group>. <article-title>The relationship between apolipoprotein E and serum oxidation-related variables is apolipoprotein E phenotype dependent</article-title>. <source>Int J Clin Lab Res</source>. <year>1998</year>;<volume>28</volume>(<issue>2</issue>):<fpage>116</fpage>–<lpage>121</lpage>.</citation>
</ref>
<ref id="bibr39-0003319712453645">
<label>39</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jofre-Monseny</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Minihane</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Rimbach</surname>
<given-names>G</given-names>
</name>
</person-group>. <article-title>Impact of apoE genotype on oxidative stress, inflammation and disease risk</article-title>. <source>Mol Nutr Food Res</source>. <year>2008</year>;<volume>52</volume>(<issue>1</issue>):<fpage>131</fpage>–<lpage>145</lpage>.</citation>
</ref>
<ref id="bibr40-0003319712453645">
<label>40</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Miyata</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>JD</given-names>
</name>
</person-group>. <article-title>Apolipoprotein E allele specific antioxidant activity and effects on cytotoxicity by oxidative insults and beta-amyloid peptides</article-title>. <source>Nat Genet</source>. <year>1996</year>;<volume>14</volume>(<issue>1</issue>):<fpage>55</fpage>–<lpage>61</lpage>.</citation>
</ref>
<ref id="bibr41-0003319712453645">
<label>41</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Strittmatter</surname>
<given-names>WJ</given-names>
</name>
<name>
<surname>Saunders</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Schmechel</surname>
<given-names>D</given-names>
</name>
<etal/>
</person-group>. <article-title>Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer’s disease</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>1993</year>;<volume>90</volume>(<issue>5</issue>):<fpage>1977</fpage>–<lpage>1981</lpage>.</citation>
</ref>
<ref id="bibr42-0003319712453645">
<label>42</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Strittmatter</surname>
<given-names>WJ</given-names>
</name>
<name>
<surname>Roses</surname>
<given-names>AD</given-names>
</name>
</person-group>. <article-title>Apolipoprotein E and Alzheimer’s disease</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>1995</year>;<volume>92</volume>(<issue>11</issue>):<fpage>4725</fpage>–<lpage>4727</lpage>.</citation>
</ref>
<ref id="bibr43-0003319712453645">
<label>43</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Corder</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Saunders</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Strittmatter</surname>
<given-names>W</given-names>
</name>
<etal/>
</person-group>. <article-title>Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late-onset families</article-title>. <source>Science</source>. <year>1993</year>;<volume>261</volume>(<issue>5123</issue>):<fpage>921</fpage>–<lpage>923</lpage>.</citation>
</ref>
<ref id="bibr44-0003319712453645">
<label>44</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Corder</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Saunders</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Risch</surname>
<given-names>NJ</given-names>
</name>
<etal/>
</person-group>. <article-title>Protective effect of apolipoprotein E type 2 allele for late-onset Alzheimer disease</article-title>. <source>Nat Genet</source>. <year>1994</year>;<volume>7</volume>(<issue>2</issue>):<fpage>180</fpage>–<lpage>184</lpage>.</citation>
</ref>
<ref id="bibr45-0003319712453645">
<label>45</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wilson</surname>
<given-names>PW</given-names>
</name>
<name>
<surname>Schaefer</surname>
<given-names>EJ</given-names>
</name>
<name>
<surname>Larson</surname>
<given-names>MG</given-names>
</name>
<name>
<surname>Ordovas</surname>
<given-names>JM</given-names>
</name>
</person-group>. <article-title>Apolipoprotein E alleles and risk of coronary disease. A meta-analysis</article-title>. <source>Arterioscler Thromb Vasc Biol</source>. <year>1996</year>;<volume>16</volume>(<issue>10</issue>):<fpage>1250</fpage>–<lpage>1255</lpage>.</citation>
</ref>
<ref id="bibr46-0003319712453645">
<label>46</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Papanas</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Katsiki</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Papatheodorou</surname>
<given-names>K</given-names>
</name>
<etal/>
</person-group>. <article-title>Peripheral neuropathy is associated with increased serum levels of uric acid in type 2 diabetes mellitus</article-title>. <source>Angiology</source>. <year>2011</year>;<volume>62</volume>(<issue>4</issue>):<fpage>291</fpage>–<lpage>295</lpage>.</citation>
</ref>
<ref id="bibr47-0003319712453645">
<label>47</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Papanas</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Maltezos</surname>
<given-names>E</given-names>
</name>
</person-group>. <article-title>Cilostazol in diabetic neuropathy: premature farewell or new beginning?</article-title> <source>Angiology</source>. <year>2011</year>;<volume>62</volume>(<issue>8</issue>):<fpage>605</fpage>–<lpage>608</lpage>.</citation>
</ref>
<ref id="bibr48-0003319712453645">
<label>48</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Papanas</surname>
<given-names>N</given-names>
</name>
</person-group>, <article-title>Maltezos E. α-Lipoic acid, diabetic neuropathy, and Nathan’s prophecy</article-title>. <source>Angiology</source>. <year>2012</year>;<volume>63</volume>(<issue>2</issue>):<fpage>81</fpage>–<lpage>83</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>